Nirmatrelvir for Outpatients with Covid-19 | NEJM

Nirmatrelvir plus ritonavir reduced the risk of Covid-19-related hospitalization or death in
unvaccinated, high-risk adults, but whether it can reduce symptom duration in a broader group is
unknown.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: nej.md/49kLhq3
#infectiousdisease #globalhealth #coronavirus #covid19 #nejm

[@adithyavikram7]

We need to start researching more on antiviral drugs ,we need to increase more antiviral drugs for future pandemics

[@dramaturge231]

But this is also saying Paxlovid did not significantly decrease incidence of hospitalization, correct?

[@MFDElk]

Covid-19-related hospitalization was one of the secondary endpoints that weren't significantly different between the two groups if I understand it correctly.